Antibodies Against Membrane Protein Targets Conference Part Two header


Suggested Conference Package: 

*Pre-Conference Short Course: Targeting of GPCRs withMonoclonal Antibodies 

PMB Part 2: Generation, Preparation and Selection ofMembrane Protein Targets Conference 


*Separate registration is required


About This Conference:

As the pharmaceutical and biotech industries shift their attentions from small molecule therapeutics to biologics, an increased amount of attention is being paid to the prospect of membrane proteins as drug targets for antibodies and other protein scaffolds.  For these large target classes, biologics offer improved selectivity, an alternative for targets with known function that have not been amenable to small molecules and the potential for using antibodies for the targeted delivery of therapeutics.  However, for the field to advance, fundamental challenges of antigen quality, screening methodology, antibody engineering and target identification must be resolved.

This two-part meeting provides a forum in which discovery biologists and protein engineers can come together to discuss next generation strategies and technologies that will allow antibody-and alternate scaffold-based therapeutics directed against these target families to advance into the clinic and beyond.

The second conference, Generation, Preparation and Selection of Membrane Protein Targets, explores approaches to generating antigens of sufficient quality and purity to enable structural and modeling studies of target engagement and the associated screening and selection strategies used to isolate high-quality binders.


GENERATION OF FUNCTIONAL MEMBRANE PROTEINS

Why VLPs for Generating Biologics to Cell Surface Proteins?

Mark Tornetta, Ph.D., Scientist, Molecular Discovery Technologies, Janssen Pharmaceuticals

High-Throughput Platforms for Expression of Bacterial and Eukaryotic Membrane Proteins

Renato Bruni, Ph.D., HeD, Eukaryotic Membrane Protein Expression, New York Structural Biology Center

Development of Engineered Crystallization Chaperones to Promote Membrane Protein Crystallization

Raquel Lieberman, Ph.D., Associate Professor, School of Chemistry & Biochemistry, Georgia Institute of Technology

Optimization of Channels and Receptors for High-Throughput Screening and Antibody Development

Susmith Mukund, Senior Research Associate, Genentech


Friday, October 10, 2014


PREPARATION OF MEMBRANE PROTEINS FOR ANTIBODY PRODUCTION

Using Purified Membrane Proteins for Antibody Development:  When and How

Christopher Koth, Ph.D., Senior Scientist, Structural Biology, Genentech

Stabilizing Membrane Protein and Membrane Protein Complex on Analytical Surface

Rick Chu, Ph.D., Lead Research Investigator, Genzyme

hallenges of Membrane Proteins Antigen Production for Antibody Generation

Ramkrishna (Ramu) Sadhukhan, Ph.D., Senior Group Leader, Global Biologics, AbbVie


ASSAYS FOR DEVELOPING MABS AGAINST MEMBRANE PROTEIN TARGETS

Therapeutic Monoclonal Antibodies Targeting APJ Receptor

Krzysztof Palczewski, Ph.D., John H. Hord Professor and Chair, Department of Pharmacology, School of Medicine, Case Western Reserve University

Characterization of a Nanobody Library against Cannabinoid Receptor CB2

Alexei Yeliseev, Ph.D., Staff Scientist, Protein Biochemistry, LMBB, NIH


ANTIBODY GENERATION, SELECTION AND SCREENING

Innovative Methods for the Generation of Nanobodies against Membrane Proteins and Their Complexes

Jan Steyaert, Ph.D., Head of Department, Structural Biology, Vrije University Brussels, Belgium

Phage Libraries and Their Application in Antibody Discovery against Membrane Proteins

Johan Fransson, Ph.D., Principal Scientist, Janssen R&D

Fluorescent Approaches for Screening and Characterizing Ligand and Antibody Binding to Membrane Proteins and Surface-Displayed Proteins in Yeast

Mark E. Dumont, Ph.D., Principal Investigator, University of Rochester Medical Center

Activity-Based Screening of Antibodies to Cell Surface Targets

Ralph Minter, Ph.D., Fellow, Technology, Antibody Discovery and Protein Engineering, MedImmune, United Kingdom

Single Domain Antibodies against GPCRs and Ion Channels

Mick Foley, Ph.D., CSO, Biochemistry, AdAlta, Australia

DOT CAG ICON 

green arrow CONFERENCE-AT-A-GLANCE 

PREMIER SPONSORS 

Cellecta 

green arrow VIEW ALL SPONSORS 

green arrow VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2013, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2014, contact:

Jon Stroup
Business Development Manager
781-972-5483
jstroup@healthtech.com